FGFR2 and cholangiocarcinoma: By contrast, evidence from FGFR2-fusion intrahepatic cholangiocarcinoma is limited and sometimes inconsistent, underscoring the need for tumor-specific interpretation of FGFR–interferon crosstalk [140,141].